The phase 1 and 2 trials resumed after the Japanese regulator gave the go-ahead. Trials in the UK, Brazil, South Africa and India had already restarted in recent weeks.
AstraZeneca CEO Pascal Soriot sought to reassure investors after the Oxford vaccine trial was halted due to a person in the UK falling sick, triggering a review of safety data.
The AstraZeneca Plc paused the trial of its leading candidate, developed with Oxford University, to study a volunteer's illness. This pause shows the system is working as it should.
Serum Institute of India, the world’s largest vaccine manufacturer, will run trials of the shot developed by SpyBiotech that uses a patented superglue tech to induce an immune response.
The protocol will now be moved to DCGI V.G. Somani, who is likely to take a ‘decision by the end of the week’ given the urgency of the Covid challenge.
India’s apex clinical trial regulation body will meet urgently to reconsider Serum Institute of India’s proposal after it revised its plan for starting Oxford vaccine's human trials in India.
Driving an electric vehicle for months, the Hyundai IONIQ5, BMW iX and now the Kia Carens Clavis electric, has convinced me of the viability of EVs for city and mid-range commutes.
With the US-India trade deal yet to get done, rupee depreciation may be helping to mitigate India’s loss of competitiveness. The other problem is extreme despondence among overseas equity investors.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS